Back |
home / stock / nvus / nvus message board
Subject | By | Source | When |
---|---|---|---|
@Fairview... all I wanted to do was dump | Giddycarol30 | investorshub | 03/15/2018 3:39:10 AM |
Yep was down a lot at lows and | FairviewInvestor | investorshub | 03/14/2018 5:38:48 PM |
@fairview Same here but looks like it was | Giddycarol30 | investorshub | 03/14/2018 5:07:18 PM |
Nice. only 5M float. nearing Green. | FairviewInvestor | investorshub | 03/14/2018 4:37:14 PM |
$NVUS is about to run ... I saw | Giddycarol30 | investorshub | 03/14/2018 4:32:53 AM |
Still Watching. Any Catalysts on Horizon? | FairviewInvestor | investorshub | 01/02/2018 9:59:12 PM |
Chart Shaping up for reversal. if we | FairviewInvestor | investorshub | 06/29/2017 7:11:23 AM |
Employee compensation in Shares.. at least they think | FairviewInvestor | investorshub | 06/21/2017 1:38:11 AM |
Future Parabolic Runner $IMO.. but from where? | FairviewInvestor | investorshub | 05/25/2017 7:15:16 PM |
been adding drips and drabs.. only couple hundred | FairviewInvestor | investorshub | 05/25/2017 7:14:50 PM |
Tiny Float, I mean really Tiny | FairviewInvestor | investorshub | 05/25/2017 7:14:15 PM |
Let's get this changed to NVUS | FairviewInvestor | investorshub | 05/25/2017 7:14:00 PM |
News, Short Squeeze, Breakout and More Instantly...
Novus Therapeutics Inc. Company Name:
NVUS Stock Symbol:
NASDAQ Market:
Novus Therapeutics Inc. Website:
Eledon to commence trading on the Nasdaq exchange under the ticker “ELDN” effective tomorrow, January 5, 2021 Eledon is well financed to complete up to four Phase 2 clinical trials of lead candidate AT-1501, a potential best in class anti-CD40L monoclonal antibody ...
IRVINE, Calif., Dec. 22, 2020 (GLOBE NEWSWIRE) -- Novus Therapeutics, Inc. (“Novus”) (NASDAQ: NVUS), a clinical stage biopharmaceutical company focused on developing life-changing, targeted medicines for patients undergoing organ or cellular transplantation, as well as those l...
Former Chief Development and Chief Operating Officer of MyoKardia, Inc. brings extensive clinical development expertise as Novus prepares to conduct up to four Phase 2 clinical trials Novus Therapeutics, Inc. (“Novus”) (NASDAQ: NVUS), a clinical stage biopharma...